https://www.selleckchem.com/products/gsk467.html
Methotrexate (MTX) or mycophenolate mofetil with tacrolimus (TAC) is used for graft-vs-host disease (GVHD) prophylaxis in unrelated cord blood transplantation (CBT). However, there is no consensus regimen for GVHD prophylaxis in CBT. We aimed to assess the efficacy and feasibility of minimum-dose, short-term MTX (MS-MTX) for GVHD prophylaxis in CBT. We retrospectively evaluated 35 consecutive adult patients who underwent CBT and received MS-MTX (6 mg/m day 1; 3 mg/m days 3 and 6, intravenously) with TAC for GVHD prophylaxis in our hospit
Like
Comment
Share
